Catch up on today’s top five analyst downgrades with this list compiled by The Fly: 1. Hologic (HOLX) downgraded to Hold from Buy at Needham with analyst Mike Matson saying the company is seeing a “massive benefit” from COVID-19 testing, but testing sales will begin to decline in 2021. 2. BNY Mellon (BK) downgraded to Underperform from Neutral at BofA with analyst Michael Carrier anticipating “muted returns” from the company after the recent market and interest-rate driven rally. 3. National Bank (NBHC) downgraded to Neutral from Buy at DA Davidson with analyst Jeff Rulis noting that the stock has outperformed its peers by about 15% year-to-date thanks to the company’s diverse revenue mix, expense controls and “steady” credit. 4. FirstEnergy (FE) downgraded to Neutral from Buy at BofA with analyst Julien Dumoulin-Smith saying disclosures in the company’s 10-Q about payments to an unnamed consultant who went on to regulate the company’s Ohio utilities in early 2019 once again put the focus on the company’s legal and financial exposure in Ohio and “would appear to align” with PUCO Chair Sam Randazzo, whose house was recently raided by the FBI. 5. Liquidia Technologies (LQDA) downgraded to Neutral from Outperform at Wedbush with analyst Liana Moussatos saying the FDA is unlikely to approve LIQ861 on the November 24 PDUFA date, likely creating a negative near-term catalyst. Moussatos does not see any positive material catalysts for the next 12 months. This list is just a portion of The Fly’s full analyst coverage. To see The Fly’s full Street Research coverage,
previous post
next post